Advances in Methylation Detection for Ovarian Cancer Screening and Diagnosis

doi:10.12280/gjfckx.20240167

Abstract

Abstract:

Ovarian cancer has the highest mortality rate and poorest prognosis in gynecologic cancers. Presently, there is a lack of effective tools for early diagnosis and early screening for ovarian cancer. Methylation plays a key role in the origin and progression of ovarian cancer. Based on liquid biopsy technique, several studies had been conducted to analyze the efficacy of cell-free DNA methylation detection in diagnosing ovarian cancer. The overall median accuracy of cell-free DNA methylation reached 85%, which is superior to traditional protein molecular markers such as CA125. The findings from methylation detection in ovarian cancer tissue were also closely related to patients' survival outcomes and drug sensitivity. The advances and improvement of methylation assays for ovarian cancer hold promise for providing novel direction and opportunities in exploring molecular strategies for diagnosing and treating.

Key words: Ovarian neoplasms, Methylation, Epigenomics, Early diagnosis, Biomarkers, tumor

SU Hai-qi, LI Lei. Advances in Methylation Detection for Ovarian Cancer Screening and Diagnosis[J]. Journal of International Obstetrics and Gynecology, 2024, 51(4): 366-369.

References 26

[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1):12-49. doi: 10.3322/caac.21820.
[2]	You B, Freyer G, Gonzalez-Martin A, et al. The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas[J]. Cancer Treat Rev, 2021,100:102294. doi: 10.1016/j.ctrv.2021.102294.
[3]	van Nagell JR Jr, Miller RW. Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women[J]. Obstet Gynecol, 2016, 127(5):848-858. doi: 10.1097/AOG.0000000000001384. pmid: 27054927
[4]	González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(10):833-848. doi: 10.1016/j.annonc.2023.07.011. pmid: 37597580
[5]	Guo XM, Miller H, Matsuo K, et al. Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature[J]. Cancers(Basel), 2021, 13(4):838. doi: 10.3390/cancers13040838.
[6]	Terp SK, Stoico MP, Dybkær K, et al. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review[J]. Clin Epigenetics, 2023, 15(1):24. doi: 10.1186/s13148-023-01440-w. pmid: 36788585
[7]	Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer[J]. Genome Med, 2017, 9(1):116. doi: 10.1186/s13073-017-0500-7. pmid: 29268796
[8]	Miller BF, PisanicIi TR, Margolin G, et al. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers[J]. Clin Epigenetics, 2020, 12(1):154. doi: 10.1186/s13148-020-00939-w. pmid: 33081832
[9]	Lukina SS, Burdennyy AM, Filippova EA, et al. Synergy between the Levels of Methylation of microRNA Gene Sets in Primary Tumors and Metastases of Ovarian Cancer Patients[J]. Bull Exp Biol Med, 2022, 173(1):87-91. doi: 10.1007/s10517-022-05499-y.
[10]	Flanagan JM, Wilson A, Koo C, et al. Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer[J]. Clin Cancer Res, 2017, 23(9):2213-2222. doi: 10.1158/1078-0432.CCR-16-1754. pmid: 27663594
[11]	Fang F, Cardenas H, Huang H, et al. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs[J]. Cancer Res, 2018, 78(3):631-644. doi: 10.1158/0008-5472.CAN-17-1492. pmid: 29229600
[12]	Fiegl H, Windbichler G, Mueller-Holzner E, et al. HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer[J]. Int J Cancer, 2008, 123(3):725-729. doi: 10.1002/ijc.23563. pmid: 18478570
[13]	Li L, Gu Y, Zhang M, et al. HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients[J]. NPJ Precis Oncol, 2023, 7(1):51. doi: 10.1038/s41698-023-00402-y. pmid: 37258600
[14]	Rusan M, Andersen RF, Jakobsen A, et al. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer[J]. Eur J Cancer, 2020, 125:121-129. doi: 10.1016/j.ejca.2019.11.012. pmid: 31865042
[15]	Nesic K, Kondrashova O, Hurley RM, et al. Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma[J]. Cancer Res, 2021, 81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774.
[16]	Fejzo MS, Chen HW, Anderson L, et al. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition[J]. Gynecol Oncol, 2021, 160(2):539-546. doi: 10.1016/j.ygyno.2020.11.008. pmid: 33229045
[17]	Flanagan JM, Wilhelm-Benartzi CS, Metcalf M, et al. Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients[J]. Ann Oncol, 2013, 24(11):2813-2818. doi: 10.1093/annonc/mdt370. pmid: 24114859
[18]	Bast RC Jr, Lu Z, Han CY, et al. Biomarkers and Strategies for Early Detection of Ovarian Cancer[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(12):2504-2512. doi: 10.1158/1055-9965.EPI-20-1057.
[19]	Tanaka Y, Mizuguchi R, Koseki N, et al. Quality assessment of enzymatic methyl-seq library constructed using crude cell lysate[J]. Biochem Biophys Res Commun, 2024,696:149488. doi: 10.1016/j.bbrc.2024.149488.
[20]	Bahado-Singh RO, Ibrahim A, Al-Wahab Z, et al. Precision gynecologic oncology: circulating cell free DNA epigenomic analysis, artificial intelligence and the accurate detection of ovarian cancer[J]. Sci Rep, 2022, 12(1):18625. doi: 10.1038/s41598-022-23149-1. pmid: 36329159
[21]	Hu WL, Zhou XH. Identification of prognostic signature in cancer based on DNA methylation interaction network[J]. BMC Med Genomics, 2017, 10(Suppl 4):63. doi: 10.1186/s12920-017-0307-9.
[22]	Papanicolau-Sengos A, Aldape K. DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis[J]. Annu Rev Pathol, 2022, 17:295-321. doi: 10.1146/annurev-pathol-042220-022304.
[23]	Lo Riso P, Villa CE, Gasparoni G, et al. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer[J]. Genome Med, 2020, 12(1):94. doi: 10.1186/s13073-020-00786-7. pmid: 33121525
[24]	Wu TI, Huang RL, Su PH, et al. Ovarian cancer detection by DNA methylation in cervical scrapings[J]. Clin Epigenetics, 2019, 11(1):166. doi: 10.1186/s13148-019-0773-3.
[25]	Barrett JE, Jones A, Evans I, et al. The DNA methylome of cervical cells can predict the presence of ovarian cancer[J]. Nat Commun, 2022, 13(1):448. doi: 10.1038/s41467-021-26615-y. pmid: 35105887
[26]	Srivastava A, Gupta A, Patidar S. Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma[J]. Clin Transl Oncol, 2021, 23(10):1967-1978. doi: 10.1007/s12094-021-02604-x. pmid: 33840014